09/07/2021 | Press release | Distributed by Public on 09/07/2021 05:12
INCORPORATION BY REFERENCE
This Report on Form 6-K (the 'Report') is hereby expressly incorporated by reference into the registrant's registration statements on Form F-3 (File nos. 333-251055, 333-245703 and 333-251065) filed with the Securities and Exchange Commission on December 1, 2020, December 2, 2020 and December 2, 2020, respectively, and the registration statement on Form S-8 (File no. 333-235692) filed with the Securities and Exchange Commission on December 23, 2019.
Following the announcement on Form 6-K dated June 15, 2021 regarding Ms. Murielle Lortie's resignation as Chief Financial Officer effective on September 3, 2021, Liminal Biosciences Inc. (the 'Company') today announced that Mr. Bruce Pritchard is appointed as Principal Financial Officer while the search for a new Chief Financial Officer continues. For a description of Mr. Pritchard's relevant business experience and background, please see the registrant's annual report on Form 20-F for the fiscal year ended December 31, 2020.